2017
Targeting EZH2 in acral lentiginous melanoma (ALM).
Izsak A, Giles K, Lui K, Weiss S, Moran U, Vega-Saenz de Miera E, Stein J, Lee A, Darvishian F, Shapiro R, Berman R, Pavlick A, Wilson M, Osman I. Targeting EZH2 in acral lentiginous melanoma (ALM). Journal Of Clinical Oncology 2017, 35: 9534-9534. DOI: 10.1200/jco.2017.35.15_suppl.9534.Peer-Reviewed Original ResearchAcral lentiginous melanomaCM cell linesCutaneous melanomaALM casesCell linesMetastatic progressionEZH2 expressionMetastatic acral lentiginous melanomaEZH2 inhibitionEZH2 inhibitorsEffects of GSK126Mean IHC scoreColony formationEZH2 protein expressionClinicopathological dataPrimary tumorLentiginous melanomaMetastatic tumorsClinical trialsHistone methyltransferase EZH2Treatment outcomesIHC scoreLow dosesTherapeutic potentialTumors
2016
Genomic characterization of acral lentiginous melanoma: Identification of altered metabolism as a potential therapeutic target.
Weiss S, Martinez C, Vega-Saenz de Miera E, Dolgalev I, Shapiro R, Heguy A, Hernando E, Kirchhoff T, Osman I. Genomic characterization of acral lentiginous melanoma: Identification of altered metabolism as a potential therapeutic target. Journal Of Clinical Oncology 2016, 34: 9524-9524. DOI: 10.1200/jco.2016.34.15_suppl.9524.Peer-Reviewed Original Research